|
| |
BioReports
AS Insights Opportunity and Valuation
Reports
| |
By the end of 2004 the world market for Colony Stimulating Factors
was valued at $3.6 billion, a growth of 11% over 2003. The market has
been growing at an average annual growth rate of 16% over the previous 5
years.
Amgen's Neupogen (Filgrastim) will lose its key patent in major
markets in 2006 opening the market for generics. Amgen is already
preparing itself for this major patent loss by concentrating its
marketing efforts on Neulasta (Peg-Filgrastim) its once-per-cycle long
acting pegylated product and by offering little or no support to
Neupogen. |
|
| |
At the end of 2004 the world market for erythropoietin was valued at
$11.1 billion, a growth of 8% over 2003. The market has been growing at
an average annual growth rate of 18% over the previous 5 years.
The market for Erythropoietin is very lucrative. Marketing costs are
low due to the well-defined patient population and distribution costs
are low due to the limited distribution outlets. Since the market is a
virtual oligopoly barriers to entry are high thus insuring high
profitability.
|
|
| |
The global market for Monoclonal Antibody (Mab) Therapeutics reached
a total of $11.2 billion in 2004. The market has been growing at an
impressive compound average annual growth rate of 42% over the previous
five years.
|
|
| |
The biopharmaceutical market has come along way since 1982 when the
first biopharmaceutical product, recombinant human insulin, was
launched. Over 130 such products are currently being marketed around the
world including thirteen blockbuster drugs.
|
|
| |
At the end of 2004 the world market for Interferon was valued at
$5.9 billion, a growth of 13% over 2003. The market has been growing at
an average annual growth rate of 17% over the previous 5 years.
The interferon market is application driven and clearly demarcated
along the lines of the type of the interferon molecule. At 60% share,
interferon Beta accounts for the main bulk of the market followed by
interferon Alfa at 37% market share. |
|
Medtech Ventures
| |
An estimated 35,000 thoracic aortic surgical and endovascular
interventions are performed every year in the developed world (10,000 in
the US alone) at a combined cost to individuals, insurance companies and
tax payers of $3.5 billion a year. |
|
| |
The treatment of Reno-Vascular Disease is currently in a state of
evolution. Current available endovascular devices allow almost all cases
of Renal Artery Stenosis to be successfully opened.
The first successful balloon angioplasty of the Renal Artery was
performed by Andreas Gruntzig in 1976 and over a decade of experience
with Renal Artery Stenting (RAS) has demonstrated that stents can have
the same benefits on acute revascularization of the Renal Arteries, as
they do in virtually all other circulations. |
|
| |
New and more advanced Retrievable Vena Cava Filters have recently
been developed and introduced resulting in renewed growth and change of
dynamics in this established market.
The majority of traditional Permanent Vena Cava Filters were placed
after failure of anticoagulation to prevent pulmonary embolism (PE).
With over 1.2 million PE cases diagnosed in the US & Europe every year
and over 300,000 related deaths, medical needs were under-served. |
|
| |
The market for Fem-Pop Angioplasty & Stenting has experienced
explosive growth recently mainly due to the launch and acceptance of
novel atherectomy devices like the SilverHawk, and the regulatory
approval of dedicated Stents.
At the end of 2005 the market was estimated at $470 million, growing
by 30% over the previous year. |
|
| |
The landscape of management options for cerebral aneurysms is
changing fast. Current evidence suggests that coil embolization of
unruptured intracranial aneurysms is usually efficacious in obliterating
aneurysms and that its safety is similar to that of surgical treatment.
The continuous improvement in coil design and composition, the
introduction of stents for the management of wide-necked cerebral
aneurysms and the advancement in guiding catheters and wires design are
improving the utility of coils in intracranial aneurysm treatment.
|
|
| |
Carotid Angioplasty and Stenting (CAS) has recently emerged as a
popular alternative to endarterectomy for the treatment of carotid
atherosclerosis. The recent approval, by the FDA, of carotid artery
stents has initiated a global market in those devices.
Guidant, Boston Scientific, Abbott, Medtronic and J&J have all
entered the market, however, this space still lends itself also to
MedTech start-ups with innovative devices specially in the embolic
protection niche.
|
|
| |
Latest research findings indicate that drug eluting stents (DES)
reduce the need for re-intervention after PTCA to a greater extent than
bare metal stents (BMS).
The market for drug eluting stents has shown explosive growth since
its inception and in 2004 it reached an estimated $4.2 billion in
revenue worldwide. |
|
BioPortfolio's BioReports catalogue is one of the most comprehensive sources of
specialized life science management reports on the internet. You can search our database by using the
links below:
If you
represent a publisher who wishes to market via BioPortfolio's BioReports service
please contact
Peter Barfoot.
| |
|
